Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

被引：16

作者：

Kimmich, Christoph R. ^{[1
,2
,3
]}

Terzer, Tobias ^{[4
]}

Benner, Axel ^{[4
]}

Hansen, Timon

Carpinteiro, Alexander ^{[5
]}

Dittrich, Tobias ^{[1
,2
]}

Veelken, Kaya ^{[1
,2
]}

Jauch, Anna ^{[6
]}

Huhn, Stefanie ^{[1
]}

Basset, Marco ^{[1
,2
,7
,8
]}

Goldschmidt, Hartmut ^{[1
,9
]}

Mueller-Tidow, Carsten ^{[1
]}

Schoenland, Stefan O. ^{[1
,2
]}

Hegenbart, Ute ^{[1
,2
]}

机构：

[1] Heidelberg Univ Hosp, Dept Internal Med 5, Div Hematol Oncol, Heidelberg, Germany

[2] Heidelberg Univ Hosp, Amyloidosis Ctr, Neuenheimer Feld 410, D-69120 Heidelberg, Germany

[3] Univ Clin, Dept Oncol & Hematol, Klinikum Oldenburg, Oldenburg, Germany

[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[5] Univ Hosp Essen, Dept Hematol, Essen, Germany

[6] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[7] Univ Pavia, Amyloidosis Res & Treatment Ctr, IRCCS Policlin San Matteo, Pavia, Italy

[8] Univ Pavia, Dept Mol Med, Pavia, Italy

[9] Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 07期

关键词：

D O I：

10.1002/ajh.26191

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E253 / E257

页数：5

共 6 条

[1] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dimopoulos, M. A. ;

Moreau, P. ;

Terpos, E. ;

Mateos, M., V ;

Zweegman, S. ;

Cook, G. ;

Delforge, M. ;

Hajek, R. ;

Schjesvold, F. ;

Cavo, M. ;

Goldschmidt, H. ;

Facon, T. ;

Einsele, H. ;

Boccadoro, M. ;

San-Miguel, J. ;

Sonneveld, P. ;

Mey, U. .

ANNALS OF ONCOLOGY, 2021, 32 (03) :309-322

[2] AL patients don't dare go without dara [J].

Dispenzieri, Angela .

BLOOD, 2020, 135 (18) :1509-1510

[3] Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial [J].

Drayson, Mark T. ;

Bowcock, Stella ;

Planche, Tim ;

Iqbal, Gulnaz ;

Pratt, Guy ;

Yong, Kwee ;

Wood, Jill ;

Raynes, Kerry ;

Higgins, Helen ;

Dawkins, Bryony ;

Meads, David ;

Hulme, Claire T. ;

Monahan, Irene ;

Karunanithi, Kamaraj ;

Dignum, Helen ;

Belsham, Edward ;

Neilson, Jeff ;

Harrison, Beth ;

Lokare, Anand ;

Campbell, Gavin ;

Hamblin, Michael ;

Hawkey, Peter ;

Whittaker, Anna C. ;

Low, Eric ;

Dunn, Janet A. .

LANCET ONCOLOGY, 2019, 20 (12) :1760-1772

[4] Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria [J].

Kimmich, Christoph R. ;

Terzer, Tobias ;

Benner, Axel ;

Dittrich, Tobias ;

Veelken, Kaya ;

Carpinteiro, Alexander ;

Hansen, Timon ;

Goldschmidt, Hartmut ;

Seckinger, Anja ;

Hose, Dirk ;

Jauch, Anna ;

Woerner, Stefan ;

Beimler, Joerg ;

Mueller-Tidow, Carsten ;

Hegenbart, Ute ;

Schoenland, Stefan O. .

BLOOD, 2020, 135 (18) :1517-1530

[5] Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome [J].

Mohan, Meera ;

Weinhold, Niels ;

Schinke, Carolina ;

Thanedrarajan, Sharmilan ;

Rasche, Leo ;

Sawyer, Jeffrey R. ;

Tian, Erming ;

van Rhee, Frits ;

Zangari, Maurizio .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (01) :67-71

[6] Management of AL amyloidosis in 2020 [J].

Palladini, Giovanni ;

Milani, Paolo ;

Merlini, Giampaolo .

BLOOD, 2020, 136 (23) :2620-2627

← 1 →